参考资料：
[1] Sharma, et al. Faricimab phase 3 DME trial significance of personalized treatment intervals (PTI) regime for future DME trials. Eye. 2021; https://doi.org/10.1038/s41433-021-01831-4
[2][3] Half-Year Report 2024: https://assets.roche.com/f/176343/x/b4e99fb76c/hy24e.pdf
[4] Khanani, A.M. Four-year outcomes of faricimab in DME: First-time safety and efficacy results from the RHONE-X long-term extension trial. Paper presented at the American Society of Retina Specialists (ASRS) 42nd Annual Meeting. Stockholm, Sweden. July 17-20, 2024
声明：
1. 本资料中涉及的信息仅供参考，请遵从医疗卫生专业人士的意见或指导
2. 本文不构成对任何药物或诊疗方式的推广或推荐
点击查看更多罗氏在招职位
欢迎关注罗氏官方招聘号
欢迎关注罗氏官方微信号
